1 Colucci G, Tsakiris DA. Thombophilie. Swiss Med Forum. 2020;20(5–6):73–78.
2 Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017;377(12):1177–87.
3 Angelillo-Scherrer A, Nagler M. Thrombophilieabklärung: Update Guidelines in den Grauzonen. Therapeutische Umschau. 2016;73(10):626–34.
4 Franco Moreno AI, Garcia Navarro MJ, Ortiz Sanchez J, Martin Diaz RM, Madronal Cerezo E, de Ancos Aracil CL, et al. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). Eur J Intern Med. 2016;29:59–64.
5 Crou-Bou M, Harrington LB, Kabrhel C. Environmental and Genetic Risk Factors Associated with Venous Thromboembolism. Semin Thromb Hemost. 2016;42:808–20.
6 Algahtani FH, Stuckey R. High factor VIII levels and arterial thrombosis: illustrative case and literature review. Ther Adv Hematol. 2019;10:1–10.
7 Kozak PM, Xu M, Farber-Eger E, Gailani D, Wells QS, Beckman JA. Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Real-World Clinical Setting. J Am Heart Assoc. 2019;8(22):e013395.
doi:10.1161/JAHA.119.013395. Epub 2019 Nov 7.
8 Alameddine R, Nassabein R, Le Gal G, Sié P, Mullier F, Blais N. Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants. Thromb Res. 2019;185:72–7.
doi:10.1016/j.thromres.2019.11.008. [Epub ahead of print].
9 Undas A, Góralczyk T. Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment. Adv Clin Exp Med. 2016;25(6):1321–30.
10 Skelley JW, White CW, Thomason AR. The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis. 2017;43(1):24–30.
11 Gupta A, Patel P, Anwar R, Villanueva D, Vasudevan V, Guevara E. Hypercoagulable workup in a community hospital setting: to test or not to test; that is the question. J Community Hosp Intern Med Perspect. 2019;9(5):392–6.
doi:10.1080/20009666.2019.1655627. eCollection 2019.
12 Favaloro EJ. Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene “Mutation” (G20210A). Semin Thromb Hemost. 2019;45(7):730–42.
13 Stepien K, Nowak K, Wypasek E, Zalewski J, Undas A. High prevalence of inherited thrombophilia and antiphospholipid syndrome in myocardial infarction with non-obstructive coronary arteries: Comparison with cryptogenic stroke. Int J Cardiol. 2019;290:1–6.
14 Pruthi RK. Optimal utilization of thrombophilia testing. Int J Lab Hematol. 2017;39(Suppl 1):104–10.
15 Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154–64.
16 Montagnana M, Lippi G, Danese E. An Overview of Thrombophilia and Associated Laboratory Testing. Methods Mol Biol. 2017;1646:113–35.
17 Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J. 2017;38(12):852–9.